Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett Ley

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Annals of the American Thoracic Society|September 2, 2017
Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary FibrosisBrett Ley
Chest|August 10, 2019
Rebuttal From Dr LeyBrett Ley
Chest|August 10, 2019
COUNTERPOINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? NoBrett Ley
American Journal of Respiratory and Critical Care Medicine|April 1, 2017
A Glimpse into the Future: Automated Quantitative Computed Tomography as a Biomarker in Idiopathic Pulmonary FibrosisBrett Ley
American Journal of Respiratory and Critical Care Medicine|January 3, 2012
Risk prediction in idiopathic pulmonary fibrosisBrett Ley, Harold R Collard
Clinical Epidemiology|December 19, 2013
Epidemiology of idiopathic pulmonary fibrosisBrett Ley, Harold R Collard
American Journal of Respiratory and Critical Care Medicine|November 17, 2015
House of Cards? Testing Fundamental Assumptions in Idiopathic Pulmonary Fibrosis EpidemiologyBrett Ley, Harold R Collard
American Journal of Physiology. Lung Cellular and Molecular Physiology|September 28, 2014
Molecular biomarkers in idiopathic pulmonary fibrosisBrett Ley, Kevin K Brown, Harold R Collard
American Journal of Respiratory and Critical Care Medicine|October 12, 2010
Clinical course and prediction of survival in idiopathic pulmonary fibrosisBrett Ley, Harold R Collard, Talmadge E King
BMC Medicine|September 25, 2015
Models of disease behavior in idiopathic pulmonary fibrosisKerri A Johannson, Brett Ley, Harold R Collard
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Annals of the American Thoracic Society|September 2, 2017
Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary FibrosisBrett Ley
Chest|August 10, 2019
Rebuttal From Dr LeyBrett Ley
Chest|August 10, 2019
COUNTERPOINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? NoBrett Ley
American Journal of Respiratory and Critical Care Medicine|April 1, 2017
A Glimpse into the Future: Automated Quantitative Computed Tomography as a Biomarker in Idiopathic Pulmonary FibrosisBrett Ley
American Journal of Respiratory and Critical Care Medicine|January 3, 2012
Risk prediction in idiopathic pulmonary fibrosisBrett Ley, Harold R Collard
Clinical Epidemiology|December 19, 2013
Epidemiology of idiopathic pulmonary fibrosisBrett Ley, Harold R Collard
American Journal of Respiratory and Critical Care Medicine|November 17, 2015
House of Cards? Testing Fundamental Assumptions in Idiopathic Pulmonary Fibrosis EpidemiologyBrett Ley, Harold R Collard
American Journal of Physiology. Lung Cellular and Molecular Physiology|September 28, 2014
Molecular biomarkers in idiopathic pulmonary fibrosisBrett Ley, Kevin K Brown, Harold R Collard
American Journal of Respiratory and Critical Care Medicine|October 12, 2010
Clinical course and prediction of survival in idiopathic pulmonary fibrosisBrett Ley, Harold R Collard, Talmadge E King
BMC Medicine|September 25, 2015
Models of disease behavior in idiopathic pulmonary fibrosisKerri A Johannson, Brett Ley, Harold R Collard
Pageof 6